Stata DX is pioneering a liquid MRI technology aimed at enhancing neurological diagnostics through the use of multiple biomarkers, including Neurofilament-light (Nf-L), pTau-217, and GFAP, among others. Their innovative point-of-care platform allows for the implementation of multi-biomarker guided disease management strategies, which can be utilized both in clinical settings and at home. The technology features multiplexed cartridges capable of analyzing up to six biomarkers simultaneously, supporting a wide assay menu that includes immunoassays, enzymatic assays, and nucleic acid detection. This approach significantly simplifies the testing process, requiring only a small volume of whole blood (30 µL) for analysis, thereby making it more accessible for patients.

The company leverages advanced sensor technology developed at Harvard's Wyss Institute, which has led to several patents and publications in the field. Their technology includes an antifouling coating that enhances the performance of electrochemical biosensors in complex biological fluids, enabling high sensitivity and multiplexed detection of biomarkers. Stata DX's research has been published in reputable scientific journals, showcasing their contributions to the field of biosensing and diagnostics, particularly in the context of neurological diseases and other health conditions. This innovative approach positions Stata DX at the forefront of biomarker solutions for clinical studies, addressing a significant market opportunity in neurology.

United States

Stata DX is a developer of a disease management eRapid technology designed to implement custom biomarker panels for clinical studies.

Stata DX

Company Details